WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for EYSUVIS™ as a short-term treatment for the signs and symptoms of the disease. The event will be held virtually on Thursday, September 17, 2020, beginning at 8:00 a.m. ET.
Scheduled to speak at the event are Edward J. Holland, M.D., Director of Cornea Services at Cincinnati Eye Institute and Professor of Ophthalmology at the University of Cincinnati and Kelly K. Nichols, O.D., M.P.H., Ph.D., F.A.A.O., Dean of the School of Optometry at the University of Alabama at Birmingham.
Additionally, Kala management will present an update on launch planning for EYSUVIS. A New Drug Applicaton (NDA) for EYSUVIS is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) goal date of October 30, 2020. If approved, Kala expects to launch EYSUVIS before year-end.
To access the event, please dial 866-300-4091 (domestic callers) or 703-736-7433 (international callers) five minutes prior to the start of the event and provide the conference ID 7985989. Additionally, a live webcast and subsequent archived recording of the presentation will be available under “Events” in the “Investors” section of the Kala website at http://kalarx.com
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the January 2019 launch of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% and its investigational product candidate, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25%, for which a New Drug Application (NDA) is under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) goal date set for October 30, 2020.